DBVT vs DFTX: fair value comparison
DBV Technologies S.A. and Definium Therapeutics, Inc. · Updated 2026-10-19
DBVT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. DFTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DBVT currently ranks higher by quality score.
| DBVT | DFTX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $9.05 | $32.10 |
| 12-month range | $8.87–$24.54 | $10.68–$48.45 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #233 of 301 Healthcare | #234 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: DBVT fair value analysis · DFTX fair value analysis